What are the key signs and symptoms of dengue fever? What are its main epidemiological characteristics and how is the disease treated? Dr. David Morens, senior adviser to the director of the National Institute of Allergy and Infectious Diseases, answers these questions and more as he explores with Dr. Gary Kohn the potential impact of an outbreak of dengue fever in the United States.
Dengue Fever: Facts & Essentials for the Physician
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
What are the key signs and symptoms of dengue fever? What are its main epidemiological characteristics and how is the disease treated? Dr. David Morens, senior adviser to the director of the National Institute of Allergy and Infectious Diseases, answers these questions and more as he explores with Dr. Gary Kohn the potential impact of an outbreak of dengue fever in the United States.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
MinuteCE®
M3: Managing the Cardiometabolic Risk in MASH
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">M3: Managing the Cardiometabolic Risk in MASH</span><span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'> </span></p>
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
<p>Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 credits
<p>What do we know now that could have changed the history of CETP inhibition?: genetics and biology </p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
MinuteCE®
How Do We Translate Real-World AF Data Into Everyday Clinical Practice?
1.00 credits
<p>How Do We Translate Real-World AF Data Into Everyday Clinical Practice?</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?